Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06861374 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy

Study acronym: BRIGHT-FIT
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis. Participants will be randomly assigned in a 1:1 ratio to receive either bivalirudin or heparin, with follow-up at 30 days and 1 year. The primary endpoint is a composite of all-cause mortality and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 30 days.
Trial Details
NCT Number NCT06861374
Lead Sponsor First Affiliated Hospital Xi'an Jiaotong University
Conditions
(from sponsor)		 ST-segment Elevation Myocardial Infarction (STEMI)
Related terms Hemorrhage, ST Elevation Myocardial Infarction
Enrollment 2,400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov